Seegene's CURECA™ Could Revolutionize PCR Automation for Laboratories

Introduction to CURECA™

Seegene Inc., a prominent name in molecular diagnostics, has captured significant attention with the presentation of its cutting-edge system, CURECA™, at the ESCMID Global 2025 conference held in Vienna. This concept video highlighted Seegene’s vision of fully automating the PCR (Polymerase Chain Reaction) process, enhancing diagnostic accuracy and laboratory efficiency. The product is slated for release in July, aiming to streamline the workflow that currently involves various pre-processing stages of distinct sample types.

The Revolutionary Aspects of CURECA™

The CURECA™ system aims to automate not just the PCR testing process but the entire workflow, from the initial sample processing to the final analysis of results. During the conference, more than 2,300 attendees, including dignitaries from Italy, Spain, Germany, France, and Canada, visited Seegene’s booth to get insights into the functionalities of CURECA™. Attendees praised the system as a significant breakthrough in the automation of molecular diagnostics.

One notable feature is its ability to handle various sample types, including stool, urine, blood, and saliva. The design of CURECA™ addresses the traditionally labor-intensive pre-processing stage, which often requires skilled personnel and is prone to human error. This ease of automation could potentially pave the way for more consistent and reliable diagnostic testing in clinical settings.

Experts Weigh In on CURECA™

Industry experts who previewed the system noted its transformative potential in molecular diagnostics. One expert remarked, "CURECA™ not only eliminates the human errors inherent in manual processing but also enables efficient testing without time or personnel constraints." Another noted, "The automation of the pre-processing stage is a true paradigm shift, distinguishing CURECA™ from previous systems."

The feedback received from participants reflects a strong desire for such innovative solutions. The modular nature of CURECA™, which allows laboratories to tailor it to their specific needs, was also highlighted as a crucial benefit. Young-Seag Baeg, Seegene’s head of strategy and planning, underlined that the CURECA™ system could significantly impact laboratory operations, especially in tackling challenging infections.

Customization and Compatibility

CURECA™ features a customizable pre-processing system called CPS (Customizable Pre-processing System), which is engineered to enhance sample preparation across multiple diagnostic fields, including molecular diagnostics, clinical chemistry, and immunological studies. The versatile system is designed for seamless integration within various laboratory workflows, promoting improved operational efficiency while optimizing space usage.

Feedback from healthcare professionals at ESCMID Global 2025 emphasized how the CPS can facilitate improved turnaround times thanks to its integrated software, which can adjust workflows based on result deadlines. This adaptability is particularly valuable for testing infectious diseases, as it alleviates the strain often placed on laboratory staff during high-demand periods.

The Path Forward with CURECA™

Seegene’s vision isn’t just about launching a new product but rather setting a benchmark in laboratory automation that encourages laboratories to rethink their workflows entirely. The modular design allows CURECA™ to be fully implemented as a comprehensive system or utilized in part, such as through the Primary Sample Aliquot System (PAS), ensuring that labs can adapt the solution to their varying operational needs.

The escalating interest shown by the scientific community signifies a shift towards a need for sophisticated diagnostic solutions. As Jong-Yoon Chun, CEO of Seegene, stated, "The enthusiastic reception of the CURECA™ concept indicates a huge demand for next-generation diagnostic solutions, and it is poised to drive significant changes in the global PCR diagnostics market."

Conclusion

Seegene’s continuous dedication to research and development has positioned it as a leader in the field of diagnostic technology, underscored by its extensive experience during the COVID-19 pandemic, where the company provided over 340 million tests globally. With CURECA™, they aim to set new standards in diagnostic automation, potentially influencing healthcare outcomes worldwide.

For more information on Seegene and their latest innovations, visit Seegene.com.